330 related articles for article (PubMed ID: 8286188)
21. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
22. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
Sharp SY; Smith V; Hobbs S; Kelland LR
Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
[TBL] [Abstract][Full Text] [Related]
23. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
24. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
[TBL] [Abstract][Full Text] [Related]
25. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
[TBL] [Abstract][Full Text] [Related]
27. Platinum coordination complexes which circumvent cisplatin resistance.
Harrap KR; Kelland LR; Jones M; Goddard PM; Orr RM; Morgan SE; Murrer BA; Abrams MJ; Giandomenico CM; Cobbleigh T
Adv Enzyme Regul; 1991; 31():31-43. PubMed ID: 1877393
[TBL] [Abstract][Full Text] [Related]
28. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
29. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
31. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
Johnson SW; Perez RP; Godwin AK; Yeung AT; Handel LM; Ozols RF; Hamilton TC
Biochem Pharmacol; 1994 Feb; 47(4):689-97. PubMed ID: 8129746
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
Yoshida M; Khokhar AR; Zhang YP; Thai G; Siddik ZH
Cancer Chemother Pharmacol; 1994; 35(1):38-44. PubMed ID: 7987975
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity and DNA damage induced by a new platinum(II) complex with pyridine and dithiocarbamate.
Marzano C; Fregona D; Baccichetti F; Trevisan A; Giovagnini L; Bordin F
Chem Biol Interact; 2002 Aug; 140(3):215-29. PubMed ID: 12204578
[TBL] [Abstract][Full Text] [Related]
34. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
35. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
36. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
[TBL] [Abstract][Full Text] [Related]
37. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
38. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
39. Cellular pharmacology of polynuclear platinum anti-cancer agents.
Roberts JD; Peroutka J; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354
[TBL] [Abstract][Full Text] [Related]
40. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
